NCT07071844
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07071844
Title BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients (BETWEEN)
Acronym BETWEEN
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GERCOR - Multidisciplinary Oncology Cooperative Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
CHU Amiens Amiens France Details
Centre Hospitalier Universitaire -Besançon Besançon France Details
Centre François Baclesse Caen France Details
Centre Hospitalier Departemental Vendee - Site Des Oudairies La Roche-sur-Yon France Details
Centre Hospitaler Universitaire de Lille Lille France Details
Hôpital privé Jean MERMOZ Lyon France Details
CHU Saint-Antoine Paris France Details
Institut Saint Catherine Paris France Details
CHU de BORDEAUX Hôpital HAUT-LEVEQUE Pessac France Details
Institut de cancérologie Strasbourg Europe Strasbourg France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field